{"schema_version":1,"assessment_id":"eoa_inverse_innovation_exp03_opportunity320_20260801","source_experiment_id":"eoa_inverse_innovation_exp03_full320_20260801","cell_id":"invariant_mode_decomposition_design__speech_language_pathology","archetype_slug":"invariant_mode_decomposition_design","domain_slug":"speech_language_pathology","title":"Mode-guided targeting for coupled dysarthria treatment responses","opportunity_summary":"Test whether reproducible multivariate speech-response modes can identify higher-leverage dysarthria probes than impairment-oriented care or a coordinate-level response model. The proposal is technically specific and safely bounded, but the existence, stability, clinical advantage, stakeholder demand, and prior-art distinctiveness of such modes remain unestablished hypotheses.","adopter_authorizer":"The prospective adopter is the licensed treating speech-language pathologist, with patient consent and withdrawal authority preserved and data collection or experimental probes governed by an approved study protocol.","scores":{"meaningful_impact":{"score":3,"rationale":"Avoiding low-leverage targets and detecting adverse coupled patterns could improve intelligibility per unit burden, but the frequency and magnitude of the proposed targeting failure are unsupported."},"stakeholder_pull":{"score":2,"rationale":"Patients, communication partners, and SLPs are identifiable beneficiaries, but the packet contains no interviews, demand evidence, workflow requests, purchasing interest, or demonstrated dissatisfaction with current targeting."},"incremental_advantage":{"score":3,"rationale":"The modal method makes a clear prospective claim against a same-data, same-complexity coordinate-level rival, but no evidence shows that coupled modes add predictive or treatment value."},"distinctiveness_plausibility":{"score":3,"rationale":"Coupled transition modeling, modal targeting, and explicit residual and drift gates form a coherent differentiation from the stated baseline and rival, while prior art is unsearched and empirical mode stability is uncertain."},"technical_implementability":{"score":3,"rationale":"The required repeated probes, measurements, blinded outcomes, fitting, and held-out checks are specified, but reliable operator estimation may be defeated by limited observations, nonlinearity, task dependence, poor conditioning, or mode drift."},"adoption_authority_feasibility":{"score":4,"rationale":"Patient consent, licensed-SLP clinical authority, protocol governance, excluded actions, stopping rules, and rollback are explicit; broader institutional approval and workflow acceptance remain untested."},"evidence_readiness":{"score":4,"rationale":"The proposal supplies observable outputs, a nearest rival, held-out evaluation, independent problem and intervention falsifiers, and a bounded feasibility study, although thresholds and empirical feasibility data are absent."},"safety_net_benefit":{"score":3,"rationale":"Residual, conditioning, spectral-gap, drift, discomfort, fatigue, voice, and breathing checks could expose unsafe or invalid recommendations and trigger return to clinician-directed care, but their reliability has not been demonstrated."},"scalability":{"score":2,"rationale":"Repeated multimodal measurement, blinded intelligibility assessment, individualized local modeling, and restrictions across tasks, diagnoses, severity, and fatigue states create substantial scaling friction."}},"score_confidence":"MODERATE","costs":{"first_evidence":{"band_2026_usd":"50K_TO_250K","scope":"A bounded single-partner feasibility study with consenting adults, repeated standardized recordings, blinded intelligibility scoring, multivariate analysis, privacy controls, and comparison with the coordinate-level rival.","confidence":"LOW","assumptions":["Existing clinical recording and measurement capacity can be used.","Enrollment and repetitions are limited to a fixed feasibility cohort.","The study does not require permanent care changes or custom regulated hardware.","Specialized clinical, statistical, coordination, and evaluation labor is included."]},"initial_deployment_startup":{"band_2026_usd":"250K_TO_1M","scope":"Development and validation of a clinician-facing analysis workflow, standardized acquisition protocols, secure data handling, training, model-quality gates, documentation, and local governance for limited clinical use.","confidence":"LOW","assumptions":["Feasibility evidence first supports continued development.","Deployment is limited to one organization or a small partner network.","Existing acoustic and clinical systems can be integrated rather than replaced.","Additional validation is required before outputs can inform care."]},"operational_launch":{"band_2026_usd":"250K_TO_1M","scope":"A controlled clinical launch covering implementation staff, clinician training, workflow integration, prospective monitoring, privacy and compliance work, technical support, and outcome evaluation.","confidence":"LOW","assumptions":["Launch remains clinician-supervised and diagnosis- and task-bounded.","No autonomous treatment selection is permitted.","The organization already has suitable recording environments and clinical personnel.","The estimate excludes broad multisite efficacy trials and generalization across dysarthria regimes."]},"annual_recurring":{"band_2026_usd":"50K_TO_250K","scope":"Per-program operation including repeated measurement, blinded or quality-controlled scoring, secure storage, model monitoring and re-estimation, clinician time, technical maintenance, and periodic safety and outcome review.","confidence":"LOW","assumptions":["Use is limited to a modest clinical program rather than system-wide deployment.","Human clinical review remains mandatory.","Data retention and privacy requirements are manageable within existing institutional infrastructure.","Material task or population expansion would require separate validation resources."]}},"research_burden":"HIGH","earliest_credible_horizon":"12_TO_36_MONTHS","pipeline_gates":{"recognizable_externally_supportable_problem":{"status":"UNCERTAIN","reason":"The packet articulates a clinically recognizable targeting failure, but it provides no external evidence that hidden coupled modes commonly cause consequential treatment errors."},"identifiable_adopter_or_authorizer":{"status":"YES","reason":"The licensed treating SLP is the clinical decision-maker, the patient controls consent and withdrawal, and an approved study protocol governs experimental data use and probe limits."},"distinct_testable_incremental_claim":{"status":"YES","reason":"Mode-guided probes are prospectively compared with a coordinate-level response model using the same observations and complexity budget, with blinded intelligibility, effort, discomfort, variability, and held-out residual outcomes."},"bounded_next_evidence_step":{"status":"YES","reason":"The authorized feasibility study limits participation to consenting clinically stable adults, uses low-risk standardized probes, fits on early repetitions, evaluates held-out observations, and makes no permanent care change."},"no_unresolved_safety_or_authority_stop":{"status":"YES","reason":"Clinical authority, consent, excluded actions, probe-specific halt criteria, invalid-model criteria, and immediate rollback to clinician-directed care are explicitly defined."},"implementation_cost_scope_and_range":{"status":"UNCERTAIN","reason":"The packet identifies major measurement, modeling, privacy, clinician, and evaluation activities, but lacks enrollment, site, instrumentation, integration, and staffing details needed to substantiate implementation ranges."}},"blocking_evidence":["Whether cross-subsystem response modes meet preregistered reproducibility, conditioning, spectral-separation, reconstruction, and drift criteria.","Whether a mode model predicts held-out intelligibility-relevant responses better than the coordinate-level rival under the same data and complexity budget.","Whether a mode-guided low-risk probe improves blinded intelligibility or participation-proximal outcomes without increasing effort, discomfort, fatigue, or variability.","Whether repeated measurement is reliable and tolerable enough to estimate individualized local operators within a practical clinical workflow.","Whether clinicians and patients regard the targeting problem and added assessment burden as important enough to support adoption.","Whether materially similar dysarthria phenotyping, multivariate response modeling, or adaptive probe-selection methods already exist."],"next_evidence_step":"Conduct a preregistered, fixed-enrollment feasibility study in consenting adults with stable acquired dysarthria. Fit modal and coordinate-level models on early standardized repetitions and compare them on held-out reconstruction, reproducibility, drift, and blinded intelligibility prediction. Only when prespecified technical and safety gates pass, compare one low-risk mode-guided probe with the coordinate-level probe on intelligibility, effort, discomfort, and variability. Stop advancement if no mode set passes all technical gates or if the mode-guided probe does not outperform the rival without added burden.","research_questions":["Do perturbations reveal reproducible cross-variable structure beyond individual-variable responses?","How many repetitions and which measures are required for acceptable conditioning, spectral separation, and held-out reconstruction?","How stable are modes across sessions, speaking tasks, cue interpretations, learning, and fatigue states?","Does the modal model improve prospective intelligibility prediction over the coordinate-level rival at equal complexity?","Does a mode-guided probe improve blinded intelligibility or participation-proximal outcomes without increasing burden or adverse signs?","Can the required acquisition, scoring, privacy, and clinician-review workflow fit within acceptable patient and service burden?","What prior methods already cover multivariate dysarthria phenotyping, treatment-response modeling, or adaptive probe selection?"],"recommendation":"PARTNERED_RESEARCH","uncertainty_constraints":["Closed-book assessment provides no evidence of prevalence, market size, stakeholder demand, realized effect size, or world novelty.","The existence and stability of clinically useful modes are hypotheses rather than established findings.","Modes cannot be interpreted as lesions, biological modules, or causal physiology without separate evidence.","Results cannot be extrapolated across diagnoses, severity levels, tasks, fatigue states, or patients.","Cost bands are resource-equivalent planning ranges based on unspecified study and deployment assumptions, not observed prices.","No live or permanent treatment change is justified by the supplied evidence."],"closed_book_prior_art_boundary":"Prior art is explicitly unsearched. This assessment recognizes only structural differentiation from the packet's stated impairment-oriented baseline and coordinate-level rival; it makes no claim of novelty relative to existing dysarthria phenotyping, multivariate treatment-response, system-identification, or adaptive probe-selection work."}